#SABC25 - Twitter Hashtag

4 months ago

Trastuzumab +/- Pert + ET + Palbo after induction chemo now @US_FDA ✅ based off PATINA. This has been the SoC in 1L HR+ HER2+ mBC since its presentation at #SABCS24 - mPFS 44.3mos vs 29.1mos (HR: 0.74) - #SABC25: At 3yr, improved CNS progression (or death) #bcsm #OncTwitter

OncBrothers's tweet photo. Trastuzumab +/- Pert + ET + Palbo after induction chemo now @US_FDA ✅ based off PATINA. This has been the SoC in 1L HR+ HER2+ mBC since its presentation at #SABCS24

- mPFS 44.3mos vs 29.1mos (HR: 0.74)
- #SABC25: At 3yr, improved CNS progression (or death)

#bcsm #OncTwitter https://t.co/cU1P6zRm7b

4

61

31

9

5K

Oncology Brothers

@OncBrothers

8 months ago

PATINA was first presented at #SABCS24 @SABCSSanAntonio and now in @NEJM! This is the SoC for 1L HR+ HER2+ mBC: Anti-HER2 + ET + Palbo after induction chemo. - mPFS 44.3mos vs 29.1mos (HR: 0.74) - #SABC25 Update: At 3yrs, improved CNS progression (or death) w/ Palbo #bcsm

OncBrothers's tweet photo. PATINA was first presented at #SABCS24 @SABCSSanAntonio and now in @NEJM! This is the SoC for 1L HR+ HER2+ mBC: Anti-HER2 + ET + Palbo after induction chemo.

- mPFS 44.3mos vs 29.1mos (HR: 0.74)
- #SABC25 Update: At 3yrs, improved CNS progression (or death) w/ Palbo

#bcsm https://t.co/PwngPLshzC

Paolo Tarantino

@PTarantinoMD

8 months ago

PATINA is now out in @nejm. Among pts with HR+/HER2+ MBC progression-free after chemo induction, adding palbociclib to 1L ET+HER2-blockade maintenance prolonged PFS from 29 mo to an astonishing 44 months (HR 0.75, p=0.02). Congrats @Otto_DFCI & coauthors! https://t.co/YoE3Pje9Be

PTarantinoMD's tweet photo. PATINA is now out in @nejm. Among pts with HR+/HER2+ MBC progression-free after chemo induction, adding palbociclib to 1L ET+HER2-blockade maintenance prolonged PFS from 29 mo to an astonishing 44 months (HR 0.75, p=0.02). Congrats @Otto_DFCI & coauthors! https://t.co/YoE3Pje9Be https://t.co/o1rRei237p

3

260

83

62

28K

3

81

29

25

12K

Rutgers Cancer Institute @RutgersCancer

10 months ago

Today @Omene_CO from @RutgersCancer and @RWJBarnabas presented findings on “Clinical Investigations into the metabolic pathways of early-stage hormone receptor positive/HER2 negative breast cancer” at the annual San Antonio Breast Conference. #SABC25

RutgersCancer's tweet photo. Today @Omene_CO from @RutgersCancer and @RWJBarnabas presented findings on “Clinical Investigations into the metabolic pathways of early-stage hormone receptor positive/HER2 negative breast cancer” at the annual San Antonio Breast Conference. #SABC25 https://t.co/4vnix8ZcTv

0

6

1

0

179

OncLive.com

@OncLive

10 months ago

Abemaciclib Monotherapy Shows Efficacy After CDK4/6 Inhibition in HR+/HER2– Breast Cancer @SABCSSanAntonio #SABC25 #bcsm https://t.co/jGVtLxUIS0

1

2

0

362

Hope Rugo @hoperugo

10 months ago

#SABC25 A Llombert phergain ctDNA dynamics HER2+ ESBC. 3/4 + at baseline. Poor clearance assoc with worse pCR and IDFS. This is an opportunity to individualize therapy based on a dynamic biomarker. @OncoAlert

hoperugo's tweet photo. #SABC25 A Llombert phergain ctDNA dynamics HER2+ ESBC. 3/4 + at baseline. Poor clearance assoc with worse pCR and IDFS. This is an opportunity to individualize therapy based on a dynamic biomarker. @OncoAlert https://t.co/uVpEu2jC6e

1

23

13

5

3K

Bridge Champ @bridge_champ

11 months ago

Bridge Champ Ambassadors on fire at #SABC25!🔥 🥉 Agustin with Team Bernal – 3rd place in the Teams event 🥇 Andrea with Team Cole – winners of the Copa Campestre side event Proud to see our ambassadors representing Bridge Champ with skill and spirit!💪 🔗https://t.co/3FIzcY5o1R

bridge_champ's tweet photo. Bridge Champ Ambassadors on fire at #SABC25!🔥
🥉 Agustin with Team Bernal – 3rd place in the Teams event
🥇 Andrea with Team Cole – winners of the Copa Campestre side event
Proud to see our ambassadors representing Bridge Champ with skill and spirit!💪
🔗https://t.co/3FIzcY5o1R https://t.co/jodLWaqGAQ

0

6

1

0

135

Top Tweets for #SABC25

Last Seen Hashtags on Sotwe

Trends for you

Most Popular Users